Acute Renal effects of Angiotensin II Management In Shock (ARAMIS-2)

Phase 2

Recruiting

• Conditions: Vasodilatory shock; Cardiovascular - Diseases of the vasculature and circulation including the lymphatic system; Renal and Urogenital - Kidney disease

• Registration Number: ACTRN12621001043820
• Lead Sponsor: Austin Health

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2021-08-09
• Last Update Posted: 24 June 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

• Adults aged 18+ years
• Vasodilatory shock (MAP <65 mmHg)
• Central venous access and an arterial line present
• Indwelling urinary catheter
• Expected to require vasopressor support for at least 24 hours
• Informed consent provided by the patient or medical treatment decision-maker

Exclusion Criteria

• Cardiac surgery patients
• >24 hours noradrenaline, metaraminol or vasopressin prior to enrolment
• Chronic haemodialysis or peritoneal dialysis
• Not expected to receive venous thromboembolism prophylaxis in the next 72 hours
• Expected survival <24 hours
• Suspected or confirmed pregnancy

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Serum creatinine (umol/L)[ Measured at baseline and every 4-6 hours post-commencement of infusion for a maximum of 7 days or until ICU discharge]